{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:00:04Z","timestamp":1791673204135,"version":"4.3.4"},"reference-count":289,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS122835"],"award-info":[{"award-number":["R01NS122835"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA229594"],"award-info":[{"award-number":["K22 CA229594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trecan.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:29:13Z","timestamp":1790022553000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Macrophage-directed therapeutic strategies in cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-3655","authenticated-orcid":false,"given":"Shweta","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Varner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.08.006_bb0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2026.01.020","article-title":"Macrophages: targets for next-generation cancer immunotherapy","volume":"44","author":"Sun","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trecan.2024.12.002","article-title":"Embracing diversity: macrophage complexity in cancer","volume":"11","author":"Hochstadt","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0040","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0045","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0050","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0055","article-title":"The immune cell atlas of human neuroblastoma","volume":"3","author":"Verhoeven","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0065","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","article-title":"PD-1\u2212 CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma","volume":"14","author":"Cappuyns","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011959","article-title":"Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9\/10 drive pathogenic IFNG+IL17+ T cells in immunotherapy-related colitis","volume":"13","author":"Tang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0075","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41588-025-02158-6","article-title":"Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring","volume":"57","author":"Yu","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2026.08.006_bb0080","article-title":"SPP1+ macrophages in colorectal cancer: markers of malignancy and promising therapeutic targets","volume":"12","author":"Xie","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.trecan.2026.08.006_bb0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","article-title":"Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment","volume":"14","author":"Werba","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0090","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0095","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.08.006_bb0105","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/2326-6066.CIR-24-1088","article-title":"Targeting myeloid Trem2 reprograms the immunosuppressive niche and potentiates checkpoint immunotherapy in NASH-driven hepatocarcinogenesis","volume":"13","author":"Wang","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3k\u03b3, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-017-02492-2","article-title":"Yolk sac macrophage progenitors traffic to the embryo during defined stages of development","volume":"9","author":"Stremmel","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70387","article-title":"Tissue-resident macrophages in cancer: friend or foe?","volume":"13","author":"Chi","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","article-title":"Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells","volume":"595","author":"Casanova-Acebes","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb0140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.trecan.2026.08.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1616","article-title":"Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models","volume":"13","author":"Martinez-Usatorre","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0155","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191869","article-title":"Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0160","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/1078-0432.CCR-16-0133","article-title":"Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies","volume":"23","author":"Quail","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0165","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0170","article-title":"New insights into the role of macrophages in cancer immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0180","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/ijo.2024.5648","article-title":"Targeting tumor-associated macrophages: critical players in tumor progression and therapeutic strategies (Review)","volume":"64","author":"Su","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0195","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-22-3645","article-title":"Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma","volume":"83","author":"Rohila","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009024","article-title":"Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001367","article-title":"Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis","volume":"8","author":"Ho","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0210","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2025.43.16_suppl.8006","article-title":"Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial","volume":"43","author":"Paz-Ares","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115009","article-title":"Tumor-associated macrophages in radiotherapy: mechanisms of polarization, immune regulation and therapeutic strategies","volume":"161","author":"Xu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0220","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb0225","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","article-title":"Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion","volume":"58","author":"Waibl Polania","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0235","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0240","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0245","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-25-0159","article-title":"Targeting myeloid cells for cancer immunotherapy","volume":"13","author":"Blanchard","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0250","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0255","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0265","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0270","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0280","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb0285","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0290","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2767-9764.CRC-22-0266","article-title":"CD47-blocking antibody ZL-1201 promotes tumor-associated macrophage phagocytic activity and enhances the efficacy of the therapeutic antibodies and chemotherapy","volume":"2","author":"Cao","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0295","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000413","article-title":"The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2026.08.006_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \u201cdon\u2019t eat me\u201d signal and activating the \u201ceat me\u201d signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0320","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1518787","article-title":"Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy","volume":"16","author":"Krishnamoorthy","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0330","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.2024027222","article-title":"Targeting CD47: many misses; hopeful for a hit","volume":"145","author":"Wilde","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.08.006_bb0335","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1182\/blood-2021-152130","article-title":"ADG153, an anti-CD47 monoclonal antibody prodrug, has strong in vivo anti-tumor activity, minimal RBC-related and antigen sink liabilities, and extended half life in comparison with benchmark clinical antibodies of the same IgG subclass","volume":"138","author":"Cai","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.08.006_bb0340","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","article-title":"CD24 and Siglec-10 selectively repress tissue damage-induced immune responses","volume":"323","author":"Chen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0345","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.1409580111","article-title":"Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer","volume":"111","author":"Laubli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb0350","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/2326-6066.CIR-22-0366","article-title":"Targeting the siglec\u2013sialic acid immune axis in cancer: current and future approaches","volume":"10","author":"Laubli","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0355","first-page":"240","article-title":"IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24\/siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy","volume":"6","author":"Li","year":"2023","journal-title":"Antib. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0360","first-page":"A917","article-title":"AL009, a fusion protein and multi-Siglec inhibitor, repolarizes suppressive myeloid cells and potentiates anti-cancer effects","volume":"9","author":"Sam Nalle","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0365","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-017-2023-x","article-title":"LILRB receptor-mediated regulation of myeloid cell maturation and function","volume":"66","author":"van der Touw","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2026.08.006_bb0370","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0375","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.2022.40.16_suppl.2571","article-title":"Evaluation of pharmacodynamic and patient enrichment biomarkers for SAR444881, a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy","volume":"40","author":"Ilana Mandel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0380","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1200\/JCO.2024.42.16_suppl.2582","article-title":"Phase 1\/2 study of NGM707, an ILT2\/ILT4 dual antagonist antibody, in advanced solid tumors: interim results from dose-escalation","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0385","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12967-024-04938-w","article-title":"Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0390","first-page":"A651","article-title":"TTX-080, a first-in-class HLA-G specific antagonist, increases distinct innate and adaptive immune cells in the tumor microenvironment and periphery","volume":"13","author":"Courtney Beers","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0395","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/imr.13265","article-title":"Antibody-mediated phagocytosis in cancer immunotherapy","volume":"319","author":"van Wagoner","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2026.08.006_bb0400","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4049\/jimmunol.177.3.1661","article-title":"Yeast \u03b2-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway","volume":"177","author":"Li","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0405","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","article-title":"Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy","volume":"34","author":"Medler","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0410","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.annonc.2022.01.023","article-title":"15P STELLAR-001: a phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors","volume":"33","author":"Bennouna","year":"2022","journal-title":"ESMO Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0415","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/eji.201646775","article-title":"Card9 controls Dectin-1-induced T-cell cytotoxicity and tumor growth in mice","volume":"47","author":"Haas","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0420","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2026.08.006_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940674","article-title":"Next generation CD40 agonistic antibodies for cancer immunotherapy","volume":"13","author":"Salomon","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0430","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.08.006_bb0435","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005584","article-title":"Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas","volume":"11","author":"Coveler","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0445","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s00262-021-02932-5","article-title":"The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo","volume":"70","author":"Deronic","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2026.08.006_bb0450","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.08.006_bb0455","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0460","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1346","article-title":"Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer","volume":"13","author":"Garris","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-023-00364-1","article-title":"Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer","volume":"7","author":"Rolfo","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0470","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.08.006_bb0475","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.immuni.2020.04.004","article-title":"Nucleic acid sensors as therapeutic targets for human disease","volume":"53","author":"McWhirter","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0480","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002408","article-title":"Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity","volume":"9","author":"Anfray","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0490","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001224","article-title":"Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration","volume":"8","author":"Sultan","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0495","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1038\/s41467-023-41438-9","article-title":"Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121302","article-title":"Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer","volume":"280","author":"Singh","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2026.08.006_bb0505","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0510","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb0515","first-page":"18","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.08.006_bb0520","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-16-1934","article-title":"Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN","volume":"23","author":"Chow","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0525","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2018.1888","article-title":"Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial","volume":"4","author":"Ferris","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0530","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005018","article-title":"Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies","volume":"10","author":"Hagerbrand","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0535","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","article-title":"Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function","volume":"81","author":"La Fleur","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0540","doi-asserted-by":"crossref","first-page":"32005","DOI":"10.1073\/pnas.2015343117","article-title":"Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells","volume":"117","author":"Eisinger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb0545","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","article-title":"Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis","volume":"15","author":"Georgoudaki","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.08.006_bb0550","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","article-title":"The biology of TREM receptors","volume":"23","author":"Colonna","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0555","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","article-title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer","volume":"24","author":"Park","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0560","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10637-024-01419-1","article-title":"A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma","volume":"42","author":"Beckermann","year":"2024","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.08.006_bb0565","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1158\/1538-7445.AM2025-3136","article-title":"EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance","volume":"85","author":"Marchante","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0570","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1582-4934.2006.tb00425.x","article-title":"Stabilin-1, a homeostatic scavenger receptor with multiple functions","volume":"10","author":"Kzhyshkowska","year":"2006","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0575","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1158\/1078-0432.CCR-18-3016","article-title":"Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8+ T-cell response against immunosuppressive tumors","volume":"25","author":"Viitala","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0580","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(25)00103-6","article-title":"Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Kontro","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0585","article-title":"Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I\/II first-in-human MATINS trial","volume":"4","author":"Rannikko","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0590","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ni760","article-title":"Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4","volume":"3","author":"Chang","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0595","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004859","article-title":"BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression","volume":"10","author":"Mandel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0600","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.immuni.2011.02.004","article-title":"Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells","volume":"34","author":"Ma","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb0605","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.08.006_bb0610","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1535-7163.MCT-22-0351","article-title":"Inhibition of LILRB2 by a novel blocking antibody designed to reprogram immunosuppressive macrophages to drive T-cell activation in tumors","volume":"22","author":"Umiker","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0615","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201811","article-title":"LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy","volume":"218","author":"Sharma","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010006","article-title":"Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors","volume":"12","author":"Taylor","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0625","first-page":"A1695","article-title":"1464 Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in patients with advanced cancers","volume":"12","author":"Shiraj Sen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0630","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2024-206538","article-title":"IO-202, a novel anti-LILRB4 antibody, with azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1B expansion cohort results","volume":"144","author":"Mannis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.08.006_bb0635","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2025.11.009","article-title":"Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells","volume":"44","author":"Yagel","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0640","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ccell.2025.12.021","article-title":"Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth","volume":"44","author":"Mateus-Tique","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0645","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0650","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0655","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0660","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0665","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0670","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10637-021-01084-8","article-title":"LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial","volume":"39","author":"Dowlati","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.08.006_bb0675","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naive or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115756","article-title":"Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor","volume":"229","author":"van de Sande","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0685","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-20-3955","article-title":"A randomized phase II study of anti-CSF1 monoclonal antibody lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple-negative breast cancer","volume":"28","author":"Kuemmel","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0690","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12705","volume":"183","author":"Masek-Hammerman","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0695","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.08.006_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.trecan.2026.08.006_bb0705","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001153","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients","volume":"8","author":"Machiels","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0710","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0715","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0720","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0725","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","article-title":"CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function","volume":"12","author":"Chun","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.08.006_bb0730","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb0735","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.trecan.2025.01.008","article-title":"Targeting PI3K\u03b3 in cancer","volume":"11","author":"Mognol","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0740","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","article-title":"New insights into SYK targeting in solid tumors","volume":"45","author":"Joshi","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trecan.2026.08.006_bb0745","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1126\/science.7624799","article-title":"Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase","volume":"269","author":"Stoyanov","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0750","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1042\/bj3260891","article-title":"Interaction of Ras with phosphoinositide 3-kinase \u03b3","volume":"326","author":"Rubio","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.trecan.2026.08.006_bb0755","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.287.5455.1049","article-title":"Central role for G protein-coupled phosphoinositide 3-kinase \u03b3 in inflammation","volume":"287","author":"Hirsch","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0760","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.287.5455.1046","article-title":"Roles of PLC-\u03b22 and -\u03b23 and PI3K\u03b3 in chemoattractant-mediated signal transduction","volume":"287","author":"Li","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb0765","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1073\/pnas.052010699","article-title":"Neutrophils lacking phosphoinositide 3-kinase \u03b3 show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis","volume":"99","author":"Hannigan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb0770","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20081268","article-title":"PI3K\u03b3 controls oxidative bursts in neutrophils via interactions with PKC\u03b1 and p47phox","volume":"419","author":"Lehmann","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.trecan.2026.08.006_bb0775","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1189\/jlb.4A0615-261RR","article-title":"Neutrophil extracellular traps release induced by Leishmania: role of PI3K\u03b3, ERK, PI3K\u03c3, PKC, and [Ca2+]","volume":"100","author":"DeSouza-Vieira","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0780","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1021\/jm051056c","article-title":"Discovery of 3,3\u2032-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction","volume":"50","author":"Palanki","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.08.006_bb0785","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb0790","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","article-title":"PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression","volume":"5","author":"Foubert","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0795","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060226","article-title":"PI3-kinase \u03b3 promotes Rap1a-mediated activation of myeloid cell integrin \u03b14\u03b21, leading to tumor inflammation and growth","volume":"8","author":"Schmid","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2026.08.006_bb0800","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb0805","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb0810","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/2159-8290.CD-15-1346","article-title":"Macrophage PI3K\u03b3 drives pancreatic ductal adenocarcinoma progression","volume":"6","author":"Kaneda","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb0815","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1541-7786.MCR-13-0682","article-title":"A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1\u03b1 and HIF2\u03b1 stability and tumor growth, angiogenesis, and metastasis","volume":"12","author":"Joshi","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0820","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0825","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0830","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.2023022202","article-title":"PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway","volume":"143","author":"Gu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.08.006_bb0835","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","article-title":"Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling","volume":"630","author":"Luo","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb0840","first-page":"1082","article-title":"Targeting a lineage-specific PI3K\u0263-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule","volume":"5","author":"Kelly","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.trecan.2026.08.006_bb0845","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi6887","article-title":"PI3K\u03b3 inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections","volume":"16","author":"Shepard","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0850","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bbamcr.2014.10.022","article-title":"Calling in SYK: SYK\u2019s dual role as a tumor promoter and tumor suppressor in cancer","volume":"1853","author":"Krisenko","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.trecan.2026.08.006_bb0855","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1535-7163.MCT-19-0947","article-title":"Macrophage Syk-PI3K\u03b3 inhibits antitumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression","volume":"19","author":"Joshi","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095893","article-title":"Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo","volume":"9","author":"Joshi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2026.08.006_bb0865","doi-asserted-by":"crossref","first-page":"41661","DOI":"10.1074\/jbc.M306491200","article-title":"Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase","volume":"278","author":"Pradip","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2026.08.006_bb0870","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41698-025-01152-9","article-title":"TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects","volume":"9","author":"Huang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0875","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148317","article-title":"Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma","volume":"14","author":"Rohila","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0880","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.08.006_bb0885","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-19-3239","article-title":"Phase I study of TAK-659, an investigational, dual SYK\/FLT3 inhibitor, in patients with B-cell lymphoma","volume":"26","author":"Gordon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0890","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6776","article-title":"A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors","volume":"13","author":"Juric","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0895","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/ITT.S494550","article-title":"The regulatory network of transcription factors in macrophage polarization","volume":"14","author":"Liu","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb0900","doi-asserted-by":"crossref","first-page":"E1144","DOI":"10.1152\/ajpendo.00002.2014","article-title":"C\/EBP\u03b1 regulates macrophage activation and systemic metabolism","volume":"306","author":"Lee","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.trecan.2026.08.006_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216638","article-title":"C\/EBP\u03b1 mediates the maturation and antitumor functions of macrophages in human hepatocellular carcinoma","volume":"585","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2026.08.006_bb0910","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","article-title":"Upregulation of C\/EBP\u03b1 inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients","volume":"27","author":"Hashimoto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0915","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0920","first-page":"A545","article-title":"A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours","volume":"9","author":"Ruth Plummer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0925","article-title":"TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors","volume":"6","author":"Plummer","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb0930","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1189\/jlb.1012531","article-title":"Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma","volume":"95","author":"Abad","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0935","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","article-title":"Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment","volume":"15","author":"Kortylewski","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb0940","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0945","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-20-1803","article-title":"Multicenter phase I\/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503\/SCOOP trial)","volume":"26","author":"Kawazoe","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0950","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40268-023-00416-8","article-title":"A phase I study to investigate the safety, tolerability and pharmacokinetics of napabucasin combined with sorafenib in Japanese patients with unresectable hepatocellular carcinoma","volume":"23","author":"Okusaka","year":"2023","journal-title":"Drugs R D"},{"key":"10.1016\/j.trecan.2026.08.006_bb0955","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","article-title":"Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors","volume":"85","author":"Kawazoe","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0960","first-page":"100","article-title":"Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study","volume":"22","author":"Shah","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb0965","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-21-4021","article-title":"Randomized, double-blind, placebo-controlled phase III study of paclitaxel \u00b1 napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb0970","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/cancers17050755","article-title":"Targeting STAT3 for cancer therapy: focusing on Y705, S727, or dual inhibition?","volume":"17","author":"Berkley","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2026.08.006_bb0975","article-title":"Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer","volume":"3","author":"Tang","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb0980","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.trecan.2026.08.006_bb0985","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/biom12030447","article-title":"Inhibition of STAT6 activation by AS1517499 inhibits expression and activity of PPAR\u03b3 in macrophages to resolve acute inflammation in mice","volume":"12","author":"Lee","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.trecan.2026.08.006_bb0990","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj7002","article-title":"Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity","volume":"8","author":"Kamerkar","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.08.006_bb0995","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175445","article-title":"Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer","volume":"134","author":"Dussold","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.08.006_bb1000","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110774","article-title":"Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy","volume":"85","author":"Yang","year":"2024","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2326-6066.CIR-14-0018","article-title":"Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328306","article-title":"Generation and characterization of antagonistic anti-human CD39 nanobodies","volume":"15","author":"Menzel","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1025","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1021\/acs.jcim.1c00590","article-title":"Identification of novel CD39 inhibitors based on virtual screening and enzymatic assays","volume":"62","author":"Zhao","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.trecan.2026.08.006_bb1030","doi-asserted-by":"crossref","first-page":"13444","DOI":"10.1021\/acs.jmedchem.0c01044","article-title":"Targeting metabolism of extracellular nucleotides via inhibition of ectonucleotidases CD73 and CD39","volume":"63","author":"Jeffrey","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.trecan.2026.08.006_bb1035","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1838036","article-title":"Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism","volume":"12","author":"Spatola","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.trecan.2026.08.006_bb1040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1045","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1050","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","article-title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","volume":"131","author":"Segal","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1055","doi-asserted-by":"crossref","first-page":"CT180","DOI":"10.1158\/1538-7445.AM2018-CT180","article-title":"Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors","volume":"78","author":"Siu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1060","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2019.37.15_suppl.2505","article-title":"Immunobiology, preliminary safety and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers","volume":"37","author":"Luke","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb1070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.531491","article-title":"IDO expression in cancer: different compartment, different functionality?","volume":"11","author":"Meireson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1075","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122239","article-title":"Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn\/AhR\/IL-6 and pol \u03b6-prevented CIN in human oral squamous cell carcinoma","volume":"335","author":"Chen","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.trecan.2026.08.006_bb1085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10637-019-00787-3","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours","volume":"38","author":"Ebata","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.08.006_bb1090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-018-0351-9","article-title":"Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors","volume":"6","author":"Nayak-Kapoor","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1095","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1100","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12885-023-11213-6","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303\/KEYNOTE-698 study","volume":"23","author":"Cicin","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-023-01416-w","article-title":"Phase I\/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma","volume":"42","author":"Huynh","year":"2024","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.trecan.2026.08.006_bb1110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noad174","article-title":"Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase I trial","volume":"26","author":"Johnson","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.trecan.2026.08.006_bb1115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002057","article-title":"Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma","volume":"9","author":"Zakharia","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1120","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan\u2013kynurenine\u2013aryl hydrocarbon axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112840","article-title":"Arginase: an emerging and promising therapeutic target for cancer treatment","volume":"149","author":"Niu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.trecan.2026.08.006_bb1130","article-title":"Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158","volume":"4","author":"Grobben","year":"2020","journal-title":"J. Struct. Biol. X"},{"key":"10.1016\/j.trecan.2026.08.006_bb1135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz244.002","article-title":"Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced\/metastatic (adv\/met) solid tumours","volume":"30","author":"Naing","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1145","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Aung Naing","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1150","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","article-title":"Liver X receptors in lipid metabolism: opportunities for drug discovery","volume":"13","author":"Hong","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb1155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/biom15040579","article-title":"Exploring the roles of liver X receptors in lipid metabolism and immunity in atherosclerosis","volume":"15","author":"Endo-Umeda","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.trecan.2026.08.006_bb1160","first-page":"A754","article-title":"657 Abequolixron (RGX-104), a first-in-class oral immunotherapy targeting the liver-X receptor (LXR), in combination with docetaxel in recurrent advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"12","author":"Mita","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1165","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7150\/jca.83856","article-title":"Acyl-coenzyme A: cholesterol acyltransferase inhibitor avasimibe suppresses tumorigenesis and induces G1-phase cell-cycle arrest by activating PPAR\u03b3 signaling pathway in bladder cancer","volume":"15","author":"Peng","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1170","first-page":"1548","article-title":"Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma","volume":"18","author":"Bi","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.trecan.2026.08.006_bb1175","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb1180","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-19-2843","article-title":"Tumor-derived prostaglandin E2 promotes p50 NF-\u03baB-dependent differentiation of monocytic MDSCs","volume":"80","author":"Porta","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1185","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","article-title":"Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy","volume":"11","author":"Pelly","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.006_bb1190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/joim.13505","article-title":"Lessons from 20 years with COX-2 inhibitors: importance of dose\u2013response considerations and fair play in comparative trials","volume":"292","author":"Stiller","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb1195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000222","article-title":"First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers","volume":"8","author":"Hong","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1200","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/2767-9764.CRC-23-0249","article-title":"Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors","volume":"3","author":"Francica","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb1205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41423-019-0315-0","article-title":"Epigenetic regulation of macrophages: from homeostasis maintenance to host defense","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114500","article-title":"Vorinostat decrease M2 macrophage polarization through ARID1A6488delG\/HDAC6\/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma","volume":"161","author":"Hsieh","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.trecan.2026.08.006_bb1215","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1164919","article-title":"Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma","volume":"5","author":"Kroesen","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.trecan.2026.08.006_bb1220","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104193","article-title":"Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections","volume":"29","author":"Bhat","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.trecan.2026.08.006_bb1230","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1235","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO-24-02612","article-title":"Phase I study of 131I-metaiodobenzylguanidine with dinutuximab \u00b1 vorinostat for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial","volume":"43","author":"Cash","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1240","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb1245","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","article-title":"SF2523: dual PI3K\/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer","volume":"18","author":"Joshi","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb1250","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41388-025-03453-6","article-title":"BRD4 regulates PAI-1 expression in tumor-associated macrophages to drive chemoresistance in colorectal cancer","volume":"44","author":"Pan","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2026.08.006_bb1255","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41467-020-15290-0","article-title":"Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction","volume":"11","author":"Yin","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb1260","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181975","article-title":"BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy","volume":"135","author":"Savardekar","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.08.006_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.trecan.2026.08.006_bb1270","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","article-title":"Dual-activity PI3K\u2013BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis","volume":"114","author":"Andrews","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2026.08.006_bb1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.103173","article-title":"DNMT1-mediated LAMA2 inhibition induces M2 macrophage polarization during prostate cancer progression","volume":"98","author":"Li","year":"2026","journal-title":"Tissue Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb1280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13578-022-00913-4","article-title":"Tumour-associated macrophages enhance breast cancer malignancy via inducing ZEB1-mediated DNMT1 transcriptional activation","volume":"12","author":"Li","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.trecan.2026.08.006_bb1285","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/2326-6066.CIR-16-0295","article-title":"Tumor-associated macrophages promote epigenetic silencing of gelsolin through DNA methyltransferase 1 in gastric cancer cells","volume":"5","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1290","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.20180479","article-title":"Repressing the repressor: Ezh2 mediates macrophage activation","volume":"215","author":"Neele","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb1295","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.574940","article-title":"EZH2-inhibited microRNA-454-3p promotes M2 macrophage polarization in glioma","volume":"8","author":"Qi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1300","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41419-022-05169-x","article-title":"Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2026.08.006_bb1305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2703","article-title":"CAIRE: a basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors","volume":"40","author":"Italiano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1310","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1315","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-024-01216-z","article-title":"Macrophage diversity in cancer dissemination and metastasis","volume":"21","author":"Mantovani","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1320","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb1325","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb1330","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb1335","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn0327","article-title":"Hematopoietic aging promotes cancer by fueling IL-1\u237a-driven emergency myelopoiesis","volume":"386","author":"Park","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.006_bb1340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.006_bb1345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2026.08.006_bb1350","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1161\/ATVBAHA.117.310097","article-title":"The CANTOS trial: one important step for clinical cardiology but a giant leap for vascular biology","volume":"37","author":"Baylis","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarran","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1360","first-page":"7450","article-title":"Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy","volume":"50","author":"Andreesen","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1370","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1375","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.006_bb1380","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb1385","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.006_bb1390","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-024-01635-5","article-title":"A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1395","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41577-024-01081-x","article-title":"Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease","volume":"25","author":"Tiwari","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1400","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.trecan.2026.08.006_bb1410","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb1415","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6579","article-title":"Cellular backpacks for macrophage immunotherapy","volume":"6","author":"Shields","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.08.006_bb1420","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.08.006_bb1425","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb1430","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1016\/j.cell.2025.10.030","article-title":"Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy","volume":"188","author":"von Locquenghien","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2026.08.006_bb1435","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.006_bb1440","doi-asserted-by":"crossref","first-page":"40798","DOI":"10.1021\/acsnano.5c09138","article-title":"In situ chimeric antigen receptor macrophage therapy via co-delivery of mRNA and immunostimulant","volume":"19","author":"Han","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.trecan.2026.08.006_bb1445","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Control. Release"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:13:30Z","timestamp":1790111610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":289,"alternative-id":["S2405803326001913"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.006","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrophage-directed therapeutic strategies in cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}